Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer

Author:

De Cobelli Ottavio12,Buonerba Carlo3,Terracciano Daniela4,Bottero Danilo1,Lucarelli Giuseppe5,Bove Pierluigi6,Altieri Vincenzo7,Coman Ioman2,Perdonà Sisto8,Facchini Gaetano9,Berretta Massimiliano10,Di Lorenzo Giuseppe3,Grieco Paolo11,Novellino Ettore11,Franco Renato12,Caraglia Michele13,Manini Claudia14,Mirone Vincenzo15,De Placido Sabino3,Sonpavde Guru16,Ferro Matteo1

Affiliation:

1. Division of Urology, European Institute of Oncology, Milan, Italy

2. Department of Urology, ‘Iuliu Hatieganu’ University of Medicine & Pharmacy, Cluj-Napoca, Romania

3. Oncologia Urologica, Dipartimento di Medicina Clinica e Chirurgia, Azienda Ospedaliera Universitaria ‘Federico II’, Napoli, Italy

4. Department of Translational Medical Sciences, University ‘Federico II’, Naples, Italy

5. Department of Emergency & Organ Transplantation – Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy

6. Department of Urology, Tor Vergata University of Rome, V.le Oxford 81, Rome, 00133, Italy

7. Department of Urology of San Giovanni di Dio & Ruggi d'Aragona Hospital, University of Salerno, Salerno, SA, Italy

8. Department of Urology, National Cancer Institute of Naples, Naples, Italy

9. Gineco-urological Department, National Cancer Institute of Naples ‘Fondazione G Pascale’, Naples, Italy

10. Department of Medical Oncology, National Cancer Institute, Aviano, Italy

11. Department of Pharmacy, University of Naples, Federico II, Naples 80131, Italy

12. Pathology Unit, National Cancer Institute ‘Fondazione G. Pascale’, Naples, Italy

13. Department of Biochemistry, Biophysics & General Pathology, Second University of Naples, Naples, Italy

14. Division of Pathology, Giovanni Bosco Hospital, Turin, Italy

15. Urology Division, University Federico II of Naples, Napoli, Italy

16. UAB (University of Alabama at Birmingham) Cancer Center, Birmingham, AL 35233, USA

Abstract

Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55–68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23–100.48). Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3